Press Releases Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Market Closed - Nasdaq Stockholm Other stock markets 11:29:42 2024-05-31 am EDT			5-day change	1st Jan Change
0.35 ^SEK	+6.06%		+25.00%	+34.62%

May. 23	Annexin Pharmaceuticals AB Elects Mikael Lönn as New Ordinary Member of the Board of Directors	CI
Apr. 30	Annexin Pharmaceuticals AB Announces Phase II Study Fully Recruited with Positive Signals	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Annexin’s rights issue 100 percent subscribed and resolution of directed issue to guarantors	May. 30	AQ
Annexin celebrates 10 years and the largest owner takes a seat on the board	May. 23	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	May. 14	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	May. 07	AQ
BioStock: Annexin's phase II study fully recruited with positive signals	Apr. 30	AQ
Last patient treated in Annexin’s RVO study - promising signals of effect and no safety concerns	Apr. 25	AQ
BioStock: Annexin towards completion of phase II study and share issue	Apr. 18	AQ
Annexin resolves on a rights issue of SEK 45.1 million guaranteed to 90 percent, subject to approval by the 2024 Annual General Meeting, which has been decided to be brought forward	Mar. 28	AQ
BioStock: Strong start for Annexin in 2024	Feb. 14	AQ
Update on Annexin´s RVO study confirms promising signals of effect	Feb. 08	AQ
Annexin presents at Redeye’s Fight Cancer event on January 24	Jan. 18	AQ
Annexin announces outcome of the rights issue and resolves on directed issues to guarantors and lenders	Dec. 18	AQ
The subscription period in Annexin Pharmaceuticals’ rights issue begins today	Nov. 30	AQ
Annexin Pharmaceuticals publishes prospectus in connection with forthcoming rights issue	Nov. 28	AQ
First patients treated with higher dose without adverse events in Annexin's RVO study	Nov. 23	AQ
Annexin granted additional patent protection in the US	Nov. 14	AQ
First patient treated in the second dose group in Annexin's RVO study	23-10-25	PR
First patient treated in the second dose group in Annexin's RVO study	23-10-25	AQ
Annexin resolves a SEK 35.6 million fully guaranteed rights issue, subject to approval of an Extraordinary General Meeting	23-10-24	AQ
BioStock: Annexin's CSO on progress in cancer initiative	23-10-18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Annexin Pharmaceuticals AB

Equities

ANNX

SE0009664154

Press Releases

Filters